advertisement
Abstract #10157 Published in IGR 6-1
Effects of brinzolamide on ocular haemodynamics in healthy volunteers
Kaup M; Plange N; Niegel M; Remky A; Arend OBritish Journal of Ophthalmology 2004; 88: 257-262
AIM: A prospective, randomized study to evaluate effects of brinzolamide on ocular hemodynamics in healthy volunteers. METHODS: Thirty volunteers (12 males, 18 females; 28.3 (SD 7.8) years) were prospectively randomized to either brinzolamide or placebo during a two-week double masked treatment trial. Examinations were performed at baseline and after two weeks of treatment. Intraocular pressure (IOP) was measured and automatic static perimetry (Humphrey field analyzer, 24-2) and contrast sensitivity (CSV 1000, Vector Vision) were performed. Retrobulbar blood flow velocities (peak systolic and end diastolic velocity) and resistive indices (RI) of ophthalmic artery, central retinal artery and of temporal and nasal short posterior ciliary arteries were measured by color Doppler imaging (Sonoline Sienna Siemens). In video fluorescein angiograms (scanning laser ophthalmoscope, Rodenstock) arteriovenous passage time (AVP, dilution curves) and peripapillary diameters of retinal arterioles and venules were measured by means of digital image analysis. RESULTS: IOP was significantly decreased by brinzolamide (p < 0.0001). Neither brinzolamide nor placebo changed visual field global indices after treatment. Contrast sensitivity at three cycles per degree was significantly higher in the placebo group (p < 0.05). Apart from an increase of RI in ophthalmic artery under placebo treatment (p < 0.05) there was no effect in retrobulbar hemodynamics in both groups. Brinzolamide therapy alone resulted in a significant reduction of AVP compared to baseline (p < 0.05), while peripapillary retinal vessels diameters remained unaffected. CONCLUSIONS: Apart from the expected decrease of IOP brinzolamide showed no significant change in retrobulbar hemodynamics, but a significant shortening of AVP. Since in glaucoma AVP is prolonged indicating vascular dysfunction this effect might be beneficial in glaucoma therapy.
Dr. M. Kaup, Department of Ophthalmology, Aachen University, Aachen, Germany
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
11.7 Treatment of bloodflow (Part of: 11 Medical treatment)
